Incyte Stock Analysis
INCY Stock | USD 52.35 0.47 0.89% |
Incyte is undervalued with Real Value of 68.47 and Target Price of 82.13. The main objective of Incyte stock analysis is to determine its intrinsic value, which is an estimate of what Incyte is worth, separate from its market price. There are two main types of Incyte's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Incyte's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Incyte's stock to identify patterns and trends that may indicate its future price movements.
The Incyte stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Incyte is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Incyte Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Incyte's ongoing operational relationships across important fundamental and technical indicators.
Incyte |
Incyte Stock Analysis Notes
About 98.0% of the company shares are owned by institutional investors. The book value of Incyte was currently reported as 23.14. The company has Price/Earnings To Growth (PEG) ratio of 0.69. Incyte had not issued any dividends in recent years. The entity had 2:1 split on the 1st of September 2000. Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Incyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2094 people. To learn more about Incyte call Herve Hoppenot at 302 498 6700 or check out https://www.incyte.com.Incyte Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Incyte's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Incyte or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Incyte generated a negative expected return over the last 90 days | |
Incyte is unlikely to experience financial distress in the next 2 years | |
Incyte has a strong financial position based on the latest SEC filings | |
Over 98.0% of the company shares are owned by institutional investors | |
Latest headline from finance.yahoo.com: Polycythemia Pipeline Insight 2024, Featuring Protagonist Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, Imago BioSciences, Incyte, Italfarmaco, Lynk and Promedior |
Incyte Upcoming and Recent Events
Earnings reports are used by Incyte to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Incyte previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
13th of February 2024 Upcoming Quarterly Report | View | |
7th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
13th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Incyte Largest EPS Surprises
Earnings surprises can significantly impact Incyte's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2017-10-31 | 2017-09-30 | 0.07 | 0.08 | 0.01 | 14 | ||
2017-08-01 | 2017-06-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2015-04-30 | 2015-03-31 | -0.1 | -0.11 | -0.01 | 10 |
Incyte Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Incyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Incyte backward and forwards among themselves. Incyte's institutional investor refers to the entity that pools money to purchase Incyte's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Lsv Asset Management | 2023-12-31 | 2.7 M | Man Group Plc | 2023-12-31 | 2.4 M | Goldman Sachs Group Inc | 2023-12-31 | 2.4 M | Pictet Asset Manangement Sa | 2023-12-31 | 2.3 M | Bellevue Group Ag | 2023-12-31 | 2.2 M | Jacobs Levy Equity Management, Inc. | 2023-09-30 | 2.1 M | Northern Trust Corp | 2023-12-31 | 2 M | Norges Bank | 2023-12-31 | 2 M | Legal & General Group Plc | 2023-12-31 | 2 M | Baker Bros Advisors Lp | 2023-12-31 | 36.2 M | Blackrock Inc | 2023-12-31 | 24.3 M |
Incyte Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 11.95 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Incyte's market, we take the total number of its shares issued and multiply it by Incyte's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Incyte Profitablity
Incyte's profitability indicators refer to fundamental financial ratios that showcase Incyte's ability to generate income relative to its revenue or operating costs. If, let's say, Incyte is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Incyte's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Incyte's profitability requires more research than a typical breakdown of Incyte's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.16 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.2 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.2. Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.09 | 0.1 | |
Return On Capital Employed | 0.11 | 0.12 | |
Return On Assets | 0.09 | 0.09 | |
Return On Equity | 0.12 | 0.19 |
Management Efficiency
Incyte has return on total asset (ROA) of 0.0646 % which means that it generated a profit of $0.0646 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.125 %, meaning that it created $0.125 on every $100 dollars invested by stockholders. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.1 in 2024. Return On Capital Employed is likely to rise to 0.12 in 2024. At this time, Incyte's Return On Assets are fairly stable compared to the past year.Last Reported | Projected for Next Year | ||
Book Value Per Share | 23.21 | 24.37 | |
Net Current Asset Value | 0.00 | 0.00 | |
Tangible Asset Value | 0.00 | 0.00 | |
Tangible Book Value Per Share | 21.96 | 23.06 | |
Enterprise Value Over EBITDA | 12.01 | 12.61 | |
Price Book Value Ratio | 2.71 | 2.84 | |
Enterprise Value Multiple | 12.01 | 12.61 | |
Price Fair Value | 2.71 | 2.84 | |
Enterprise Value | 12.7 B | 13.4 B |
The analysis of Incyte's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Incyte's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Incyte Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.672 |
Technical Drivers
As of the 19th of April, Incyte retains the Market Risk Adjusted Performance of (0.70), risk adjusted performance of (0.1), and Standard Deviation of 1.3. Incyte technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down thirteen technical drivers for Incyte, which can be compared to its competitors. Please check out Incyte market risk adjusted performance and treynor ratio to decide if Incyte is priced fairly, providing market reflects its last-minute price of 52.35 per share. Given that Incyte has information ratio of (0.22), we strongly advise you to confirm Incyte's regular market performance to make sure the company can sustain itself at a future point.Incyte Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Incyte middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Incyte. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Incyte Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Incyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Incyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Incyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Baker Bros. Advisors Lp over two weeks ago Acquisition by Baker Bros. Advisors Lp of 543 shares of Incyte subject to Rule 16b-3 | ||
Whitfield Roy A over a year ago Sale by Whitfield Roy A of 30000 shares of Incyte |
Incyte Predictive Daily Indicators
Incyte intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Incyte stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 41156.55 | |||
Daily Balance Of Power | (0.47) | |||
Rate Of Daily Change | 0.99 | |||
Day Median Price | 52.5 | |||
Day Typical Price | 52.45 | |||
Price Action Indicator | (0.38) | |||
Period Momentum Indicator | (0.47) |
Incyte Corporate Filings
F4 | 2nd of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 1st of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 27th of March 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 25th of March 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 16th of February 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 14th of February 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of February 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 24th of January 2024 An amended filing to the original Schedule 13G | ViewVerify |
Incyte Forecast Models
Incyte's time-series forecasting models are one of many Incyte's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Incyte's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Incyte Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Incyte prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Incyte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Incyte. By using and applying Incyte Stock analysis, traders can create a robust methodology for identifying Incyte entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | 0.23 | 0.24 | |
Operating Profit Margin | 0.17 | 0.18 | |
Net Profit Margin | 0.16 | 0.17 | |
Gross Profit Margin | 0.93 | 1.39 |
Current Incyte Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Incyte analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Incyte analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
82.13 | Buy | 23 | Odds |
Most Incyte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Incyte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Incyte, talking to its executives and customers, or listening to Incyte conference calls.
Incyte Stock Analysis Indicators
Incyte stock analysis indicators help investors evaluate how Incyte stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Incyte shares will generate the highest return on investment. By understating and applying Incyte stock analysis, traders can identify Incyte position entry and exit signals to maximize returns.
Begin Period Cash Flow | 3 B | |
Common Stock Shares Outstanding | 225.9 M | |
Total Stockholder Equity | 5.2 B | |
Tax Provision | 218.9 M | |
Quarterly Earnings Growth Y O Y | 6.324 | |
Property Plant And Equipment Net | 777 M | |
Cash And Short Term Investments | 3.7 B | |
Cash | 3.2 B | |
Accounts Payable | 109.6 M | |
Net Debt | -3.2 B | |
50 Day M A | 57.8002 | |
Total Current Liabilities | 1.2 B | |
Other Operating Expenses | 3 B | |
Non Current Assets Total | 2.1 B | |
Forward Price Earnings | 11.3895 | |
Non Currrent Assets Other | 260.9 M | |
Stock Based Compensation | 215.9 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.Note that the Incyte information on this page should be used as a complementary analysis to other Incyte's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for Incyte Stock analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Incyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.324 | Earnings Share 2.65 | Revenue Per Share 16.526 | Quarterly Revenue Growth 0.093 | Return On Assets 0.0646 |
The market value of Incyte is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte's value that differs from its market value or its book value, called intrinsic value, which is Incyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte's market value can be influenced by many factors that don't directly affect Incyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.